New clinical research shows that a noninvasive test, the Breast Biophysical Examination (BBE), may help physicians more effectively detect breast cancer, as well as identify women who do not have cancer. The research, funded in part by the National Cancer Institute, was presented at the 17th Annual San Antonio Breast Cancer Symposium.
WILMINGTON, Del--Zeneca Group PLC, London, the parent company of Zeneca Pharmaceuticals, has entered into an agreement to purchase a 50% interest in Salick Health Care, Inc., Los Angeles, a provider of health-care services to patients with cancer and other complex illnesses. It may be the first time a pharmaceutical company has purchased a health-care provider.
Dr. Bishop provides a round-up of presentations given at the Hematologic Malignancies symposium, held in conjunction with the Mid-Atlantic Oncology Program's 13th Annual Scientific Conference.
ACS Panel : Thorough Evaluation May Point to a Reversible Cause of Post-prostatectomy Urinary Incontinence
PHILADELPHIA--Urinary incontinence probably occurs as a complication of radical prostatectomy more often than series reported in the literature suggest, said Jerry G. Blaivas, MD, in a panel discussion of complications of prostate cancer held at the American Cancer Society's National Conference on Prostate Cancer.
Approximately one third of patients with epithelial ovarian cancer present with localized or early-stage disease. Prognostic features identify certain subsets of patients with good risk characteristics who do not require adjuvant
NEW YORK--Neupogen, Amgen's recombinant granulocyte colony-stimulating factor (G-CSF, filgrastim) has received FDA approval for use in treating severe chronic neutropenia.
Tamoxifen (Nolvadex), a nonsteroidal antiestrogen, was first approved by the FDA for the treatment of patients with breast cancer in 1978. Large clinical trials have demonstrated a recurrence-free and overall survival benefit
LONDON, UK--As Oncology News International (ONI) went to press, we received news that Zeneca Group PLC has agreed to buy a 50% interest in Salick Health Care, Inc (Los Angeles). The agreement is subject to shareholder approval and US regulatory review, the company said.
DALLAS--Two pediatricians at The University of Texas Southwestern Medical Center at Dallas have established the Umbilical Stem Cell Project to procure, test, and store human umbilical cord and placental blood for use as an alternative to bone marrow in allogeneic transplant patients who lack a related compatible marrow donor.
NASHVILLE--Results of a trial of positive-selection purging in breast cancer patients undergoing high-dose chemotherapy/autologous bone marrow or peripheral blood transplantation show that patients who have no evidence of breast cancer in the graft after purging have longer progression-free survival at a median follow-up of 18 months than patients who have persistent evidence of tumor. Purging is performed by selection of CD34+ marrow or peripheral blood progenitor cells (PBPCs).
The following are excerpts from a speech given by Bernard Fisher, MD, Distinguished Service Professor of Surgery, University of Pittsburgh, School of Medicine, at the American Society of Clinical Oncology's Fall 1994 Educational Conference in Atlanta, Georgia.
In the 1970s, a radical mastectomy represented the sole option for women with breast cancer. Years later, when the issue of quality of life was raised, the era of reconstructive surgery, via silicone gel breast implants--internal prostheses, was born. For
NEW YORK--Yogi Berra had the last word at a panel discussion on health-care reform sponsored by the Medical Society of the State of New York. Television talk show host Larry King moderated the discussion and fielded the caustic remarks of doctors, pharmacists, and medical students who packed a Waldorf-Astoria ballroom to debate whether quality medical care can be maintained under health-care reform.
TARRYTOWN, NY--A nationwide study to test whether a multidimensional approach can change schoolchildren's nutritional habits and behavior for the better is nearing its final stage, Elaine Stone, PhD, of the National Heart, Lung and Blood Institute said at a symposium marking the 25th anniversary of the American Health Foundation.
A study published in the June 1, 1994 issue of the journal Blood demonstrates that amifostine (Ethyol), a selective cytoprotective agent, significantly shortens the time to bone marrow recovery in breast cancer patients undergoing high-dose